allogeneic– tag –
-
GC Cell’s CAR-NK Therapy GCC2005 Approved for Compassionate Use in Refractory T-Cell Lymphoma at SNUH, South Korea
Korea Biomedical Review South Korea Overview GC Cell's CAR-NK cell therapy, GCC2005, has received approval for compassionate use in patients with refractory T-cell lymphoma at Seoul National University Hospital (SNUH) in South Korea. Thi... -
UCLA Scientists Mass-Produce Ready-to-Use Cord Blood-Derived T Cells for Solid Tumors in 6 Weeks at $5,000/Dose, Avoiding GvHD Risk
UCLA USA Overview UCLA researchers have developed a platform to mass-produce cancer-fighting T cells from cord blood stem cells, engineered to target solid tumors. This innovative approach generates trillions of therapeutic cells (thousa... -
Democratizing Immunotherapy: Tec de Monterrey Pioneers Cost-Effective NK Cell Production Using Autologous Plasma
Facebook (Tec de Monterrey) Mexico Overview A research team at Tec de Monterrey's Toluca campus in Mexico has developed an innovative method to optimize natural killer (NK) cell cultures, utilizing readily available autologous human plas... -
Northway Biotech Unveils €61M Lithuanian Facility to Industrialize CAR-T, Integrating Vector Supply for Next-Gen Therapies
Invest Lithuania Lithuania Overview Northway Biotech has inaugurated a €61 million, 3,500 sq. meter CDMO facility in Vilnius, Lithuania, designed to industrialize the manufacturing of allogeneic CAR-T and other advanced cell and gene the... -
Cell-Easy Expands Toulouse R&D to Scale Allogeneic NK Cell Therapy (10x Cost Reduction), Optimize G-Rex® CAR-T, and Advance iPSC-Derived Beta Cells
Cell-Easy (press release) France Overview Cell-Easy, a CDMO, announced the expansion of its Toulouse R&D facilities to accelerate three next-generation cell therapy manufacturing programs. The company aims for a ten-fold cost reducti... -
Lineage Cell Therapeutics Secures US Patent for AlloSCOPE™ 5D Platform, Advancing Scalable Allogeneic iPSC Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics has been granted a U.S. Patent for its proprietary AlloSCOPE™ 5D manufacturing platform, designed for high-volume, low-passage, undifferentiated, and genetically stable pluripotent ste... -
CAR-T Cell Therapy Manufacturing Breakthrough: Automated Bioreactors Cut Production Time Below 48 Hours, Reduce Costs by 35%
PMC USA Overview Recent research highlights significant advances in CAR-T cell therapy manufacturing, with automated bioreactors enabling point-of-care biomanufacturing that reduces cell product time to less than 48 hours and cuts costs ... -
AI-Integrated Bioreactors Revolutionize Allogeneic Cell Therapy Manufacturing, Unlocking Scalability and Affordability
sanandres.uep.edu.py Paraguay Overview Allogeneic cell therapy manufacturing is undergoing a significant transformation, driven by the integration of automated, closed-system bioreactors and AI/machine learning for real-time monitoring. ... -
2026 iPSC Industry Report: Allogeneic Therapies Surpass Autologous, Diabetes, Parkinson’s, AMD Clinical Trials Progress
BioInformant Global Overview The 2026 iPSC Industry Report by BioInformant details advancements in iPSC technology for therapeutic applications, disease modeling, drug discovery, personalized medicine, and toxicity testing. Notably, allo... -
Cellipont Bioservices Supports Six Cell Therapy Programs Towards 2026 IND Filings, Highlighting CDMO Market Growth
Cellipont Bioservices (via Contract Pharma news) USA Overview Texas-based cell therapy CDMO Cellipont Bioservices announced it is supporting six client projects anticipated to reach Investigational New Drug (IND) submission in 2026. Thei...
